Study on Radiation Therapy Before CD19 CAR-T Cell Treatment for High-Risk Large B-Cell Lymphoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor score: 40
Inactive
ClinicalTrials ID:NCT06104592
This clinical trial is testing the safety and effectiveness of using radiation therapy before CD19 CAR-T cell treatment in patients with large B-cell lymphoma who have large tumors (5 cm or bigger).
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study aims to evaluate if using radiation therapy before CD19 CAR-T cell treatment is safe and effective for patients with large B-cell lymphoma (LBCL) who have large tumors. The trial is open to patients with tumors measuring 5 cm or more, and it will assess how well this approach works in controlling the disease.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with diffuse large B-cell lymphoma (DLBCL) and planning to receive treatment at Moffitt Cancer Center.
- Able to understand and willing to sign a consent form to participate in the study.
- Eligible for CAR T-cell therapy (axicabtagene ciloleucel) for LBCL and related types as per standard care guidelines.
- Have a performance status score of 0 to 2, indicating good overall health.
- Have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
- Able to receive radiation therapy to all visible cancer sites.
- No signs of cancer in the central nervous system.
- Have adequate bone marrow and organ function as per study guidelines.
- Agree to use effective birth control methods during the study to prevent pregnancy.
- Men must take precautions to avoid fathering a child during the study.
- Women of childbearing potential must have a negative pregnancy test before starting treatment and agree to use effective birth control.
- Women who are not of childbearing potential (surgically sterile or postmenopausal for 12 months) are eligible.
Exclusion Criteria
- Currently receiving or have recently received another investigational treatment within 4 weeks before the study.
- Have had previous CAR T-cell therapy.
- Unable to safely receive radiation therapy to all cancer sites.
- Have significant heart disease or unstable heart conditions.
- Have uncontrolled or untreated infections.
- Known HIV positive status.
- Active or chronic hepatitis B infection unless viral load is undetectable with treatment.
- History of hepatitis C infection unless cleared with treatment.
- Require ongoing use of steroids or immunosuppressant medications.
- Any condition that may interfere with participation or pose a risk to the patient.
- Unlikely to complete all study visits or procedures.
- Women who are pregnant or breastfeeding. Women who are surgically sterile or postmenopausal for 12 months are not considered of childbearing potential.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.
